Stock chart
Analyses on Seach Medical (5)
- May 29, 2026
- March 26, 2026March 26, 2026
- Follow-up
Seach Medical: Counterparty Risk Across the Production and Distribution Chain
Seach ended 2025 with adequate liquidity, but parts of its production and distribution chain still carry real counterparty risk: roughly NIS 4.8m of exposure to a producer under stay proceedings, a NIS 2.0m customer loan extended into June 2026, and the Telcan case still sitting…
- Follow-up
Seach Medical: Pharmacy Economics After the Impairment
Seach’s pharmacy layer is providing partial revenue stability and tighter contact with the end customer, but after three years of goodwill write-downs it still has not proved a return strong enough to justify the capital and expectations built around it. That makes the 2025 impa…
- Follow-up
Seach Medical: How Much Financial Flexibility Really Remains After the 2026 Dividend
The 2026 dividend does not put Seach into immediate liquidity stress, but it uses a meaningful part of the 2025 cash cushion and therefore raises the proof bar: the company now has to show that operating cash flow can repeat without another unusually large receivables release.
Seach Medical 2025: Cash Stayed Strong, but 2026 Is Still a Proof Year
Seach proved in 2025 that its cash generation and balance-sheet resilience are better than the accounting headline suggests, but it still has not proved that its vertical integration is creating a new earnings tier. That is why 2026 looks like a proof year rather than a harvest…
